+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Prostate Cancer Drugs Global Market Report 2020

  • ID: 4871573
  • Report
  • December 2019
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott
  • Bayer AG
  • Ferring Pharmaceuticals
  • Janssen Biotech
  • Merck Sharp & Dohme
  • Pfizer
  • MORE
Prostate Cancer Drugs Market Global Report 2020 from the author provides strategists, marketers and senior management with the critical information they need to assess the global prostate cancer drugs market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the prostate cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Prostate Cancer Drugs Market Global Report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market:
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
Scope
  • Markets Covered: 1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer 2) By Therapy: Hormonal Therapy, Chemotherapy , Immunotherapy, Targeted Therapy 3) By End User: Hospitals, Clinics, Others
  • Companies Mentioned: Astellas Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bayer AG
  • Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
  • Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
  • Time Series: Five years historic and forecast.
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott
  • Bayer AG
  • Ferring Pharmaceuticals
  • Janssen Biotech
  • Merck Sharp & Dohme
  • Pfizer
  • MORE
1. Executive Summary

2. Prostate Cancer Drugs Market Characteristics

3. Prostate Cancer Drugs Market Size And Growth
3.1. Global Prostate Cancer Drugs Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Prostate Cancer Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Prostate Cancer Drugs Market Segmentation
4.1. Global Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Hormone Sensitive Prostate Cancer
  • Hormone Refractory Prostate Cancer
4.2. Global Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Hormonal Therapy
  • Chemotherapy
  • Immunotherapy
  • Targeted Therapy
4.3. Global Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
  • Hospitals
  • Clinics
  • Other
5. Prostate Cancer Drugs Market Regional And Country Analysis
5.1. Global Prostate Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Prostate Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. Asia-Pacific Prostate Cancer Drugs Market
6.1. Asia-Pacific Prostate Cancer Drugs Market Overview
6.2. Asia-Pacific Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.4. Asia-Pacific Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. China Prostate Cancer Drugs Market
7.1. China Prostate Cancer Drugs Market Overview
7.2. China Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.4. China Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. India Prostate Cancer Drugs Market
8.1. India Prostate Cancer Drugs Market Overview
8.2. India Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.4. India Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. Japan Prostate Cancer Drugs Market
9.1. Japan Prostate Cancer Drugs Market Overview
9.2. Japan Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.4. Japan Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. Australia Prostate Cancer Drugs Market
10.1. Australia Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.3. Australia Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. Indonesia Prostate Cancer Drugs Market
11.1. Indonesia Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.3. Indonesia Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. South Korea Prostate Cancer Drugs Market
12.1. South Korea Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.3. South Korea Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. Western Europe Prostate Cancer Drugs Market
13.1. Western Europe Prostate Cancer Drugs Market Overview
13.2. Western Europe Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.4. Western Europe Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK Prostate Cancer Drugs Market
14.1. UK Prostate Cancer Drugs Market Overview
14.2. UK Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.4. UK Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. Germany Prostate Cancer Drugs Market
15.1. Germany Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.3. Germany Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. France Prostate Cancer Drugs Market
16.5. France Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.6. France Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.7. France Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. Eastern Europe Prostate Cancer Drugs Market
17.1. Eastern Europe Prostate Cancer Drugs Market Overview
17.2. Eastern Europe Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.4. Eastern Europe Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. Russia Prostate Cancer Drugs Market
18.1. Russia Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.3. Russia Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. North America Prostate Cancer Drugs Market
19.1. North America Prostate Cancer Drugs Market Overview
19.2. North America Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.4. North America Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA Prostate Cancer Drugs Market
20.1. USA Prostate Cancer Drugs Market Overview
20.2. USA Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.4. USA Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. South America Prostate Cancer Drugs Market
21.1. South America Prostate Cancer Drugs Market Overview
21.2. South America Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.4. South America Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. Brazil Prostate Cancer Drugs Market
22.1. Brazil Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.3. Brazil Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. Middle East Prostate Cancer Drugs Market
23.1. Middle East Prostate Cancer Drugs Market Overview
23.2. Middle East Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.4. Middle East Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. Africa Prostate Cancer Drugs Market
24.1. Africa Prostate Cancer Drugs Market Overview
24.2. Africa Prostate Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Prostate Cancer Drugs Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.4. Africa Prostate Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. Prostate Cancer Drugs Market Competitive Landscape And Company Profiles
25.1. Prostate Cancer Drugs Market Competitive Landscape
25.2. Prostate Cancer Drugs Market Company Profiles
25.2.1. Astellas Inc.
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. AstraZeneca plc
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Johnson & Johnson
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Sanofi S.A
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Bayer AG
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Prostate Cancer Drugs Market

27. Prostate Cancer Drugs Market Trends And Strategies

28. Product Pipeline Analysis

29. Prostate Cancer Drugs Market Future Outlook and Potential Analysis

30. Appendix
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott
  • Bayer AG
  • Ferring Pharmaceuticals
  • Janssen Biotech
  • Merck Sharp & Dohme
  • Pfizer
  • MORE
The prostate cancer drugs market consists of sales of various drugs used for the prevention and treatment of prostate cancer. Prostate cancer is one of the most common types of cancer caused due to uncontrollable development of cells in the prostate gland in men that produces the seminal fluid that nourishes and transports sperm. Some of the possible treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy and targeted therapy.

The global prostate cancer drugs market was valued at about $7.6 billion in 2018 and is expected to grow to $10.38 billion at a CAGR of 8.1% through 2022.

North America was the largest region in the prostate cancer drugs market in 2016. This region is expected to remain the largest during the next five years. The prostate cancer drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

The increasing male geriatric population is a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According to the United Nations (UN), there were around 962 million people aged 60 or above globally, accounting for 13% of the global population in 2017. The population aged 60 or above is also growing at a rate of around 3% per year. The American Cancer Society's statistics for prostate cancer in the USA states that about 6 prostate cancer cases in 10 are diagnosed in men aged 65 or above, and it is rare for men aged less than 40.

Recurrent/non-responsive prostate cancer is major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to recurrence or spread of the cancer after an initial treatment. Prostate cancer can recur locally in the tissue next to the prostate, the surrounding lymph nodes in the pelvis or lymph nodes outside this area, tissues next to the prostate (such as the muscles that help control urination, the rectum, or the wall of the pelvis). The cancer can also travel through the bloodstream and recur in bones or other organs. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment.

The use of combination therapy to treat prostate cancer is an emerging trend in the market. This is mainly because in some cases of prostate cancer, monotherapy has not been effective for the patients. In this regard, companies in the prostate cancer drugs market are investing more in combination therapy for the treatment of prostate cancer. For example, in February 2018, Pfizer announced the results of its Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC), which show that the use of XTANDI® (enzalutamide) in combination with androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to using ADT alone. Similarly, other combination therapies such as a combination of radiation therapy and androgen deprivation therapy for men with recurrent prostate cancer, and using chemotherapy drug docetaxel (Taxotere) along with ADT are also being used to treat prostate cancer.

The prostate cancer drugs market in the USA is regulated by the FDA which is responsible for approval of new drugs and lays down regulations related to treatment of prostate cancer. In February 2018, the FDA approved Erleada (apalutamide) for the treatment of prostate cancer that has not spread (non-metastatic), but continues to grow despite treatment with hormone therapy (castration-resistant). This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market.

In October 2018, Novartis acquired Endocyte for $2.1 billion. This acquisition will help Novartis to develop expands its radiotherapy capabilities for the treatment of prostate cancer. Endocyte is a biopharmaceutical company involved in developing targeted therapies for the personalized treatment of cancer. It was founded in 1996 and headquartered in Indiana, the USA.

Major players in the market are Astellas Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bayer AG
Note: Product cover images may vary from those shown
5 of 5
  • Astellas Inc.
  • AstraZeneca plc
  • Johnson & Johnson
  • Sanofi S.A
  • Bayer AG
  • Roche
  • Abbott
  • Pfizer
  • Norvaris
  • F. Hoffmann-La Roche AG
  • Tolmar Inc
  • AbbVie
  • Siemens Healthcare GmbH
  • Genomic Health
  • OPKO
  • Siemens Healthcare
  • MDx Health
  • Myriad Genetics
  • Janssen Biotech
  • Clovis Oncology
  • Merck Sharp & Dohme
  • Dendreon
  • Ferring Pharmaceuticals
  • GlaxoSmithKline
  • Ipsen
  • Merck & Co.
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll